
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated a strong financial performance, with fourth-quarter gross margins expected to range between 73% and 75%, and a full-year gross margin rising to approximately 72%, highlighting the company’s operational efficiencies and growth strategy. The company reported $9.5 million in revenue, reflecting a 10% year-over-year increase, driven by successful distributor sales and improved manufacturing efficiencies, while also achieving significant progress with its DrugSorb-ATR product. Management's strategic financial maneuvers, such as amending the credit agreement to enhance liquidity, combined with positive clinical data and expanding evidence for their products in critical care, further bolster the positive outlook for CytoSorbents's stock.
Bears say
CytoSorbents Corp reported fourth-quarter revenue of approximately $9.2 million, showing no growth compared to the previous year, while full-year revenue reached about $37 million, reflecting a modest increase of 4%. The company faces challenges due to patient imbalances observed in the initial phase of its U.S. operations, contributing to a lack of momentum in revenue growth. Furthermore, shares are perceived to be trading at a distressed valuation that does not align with underlying financial fundamentals.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares